Basic rules to respond to PD-1 blockade cancer immunotherapy.

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• 15 years of clinical data and biopsy analyses from cancer patients treated with anti-PD-1 antibodies inform current understanding.
• Durable clinical responses to anti-PD-1 therapy depend on specific prerequisites for immune system engagement.

Purpose of the Study:

• To elucidate the fundamental requirements for inducing durable clinical responses to anti-PD-1 therapy.
• To outline the mechanisms by which anti-PD-1 blockade enhances antitumor immunity.

Main Methods:

• Analysis of clinical trial data and patient biopsies from cancer patients receiving anti-PD-1 therapy.
• Identification of key immunological factors and cancer cell characteristics associated with treatment response.

Main Results:

• Effective anti-PD-1 therapy necessitates immunogenic cancers recognizable by antitumor T cells.
• Pre-existing, activated antitumor T cells are crucial; they may be suppressed by cancer cell PD-1 ligand expression.
• PD-1 blockade reinvigorates T cells, increasing interferon-gamma production and cancer cell immunogenicity.
• Neoadjuvant anti-PD-1 therapy before surgery improves outcomes by preserving antitumor T cells.

Conclusions:

• The combination of cancer immunogenicity, pre-existing T cell immunity, and PD-1 pathway blockade drives clinical responses.
• Understanding these requirements optimizes the application of anti-PD-1 therapy for durable cancer treatment benefits.